Research output

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

  • Gadgeel, S.
  • Shaw, A. T.
  • Barlesi, F.
  • Crino, L.
  • Yang, J. C.
  • Dingemans, A.C.

  • Kim, D.
  • de Marinis, F.
  • Schulz, M.
  • Liu, S.
  • Gupta, R.
  • Kotb, A.
  • Ou, S. I.

Associated organisations

    Research areas

  • alectinib, ALK positive, central nervous system, cumulative incidence rates, disease progression, non-small-cell lung cancer, phase II, CELL LUNG-CANCER, OPEN-LABEL, CRIZOTINIB
View graph of relations

Details

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalBritish Journal of Cancer
Volume118
Issue number1
DOIs
Publication statusPublished - 9 Jan 2018